MNKDMannKind Corporation
$3.29-39% 1Y
$3.29
$2.2852 weeks$6.21
MNKD in its own filings
MNKD's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
435
Events found in the filings · across 1,672 filings · the record starts in 2004
- Hard flags
- 2
Hard flags
- Most recent filing
- Aug 21, 2026
Most recent filing · Form 8-K
- Record starts
- Sep 1, 2004
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Late periodic reporthistorical
- 2016-03-01
- Delisting notice / listing-rule failurehistorical
- 2016-09-22
- SEC comment-letter activity25 occurrences
- 2025-07-24
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 21, 2026On August 21, 2026, MannKind Corporation (the “Company”) filed a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-285286) with the Securities and Exchange Commission.Other event · Form 8-K
- Aug 5, 2026MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Jul 24, 2026On July 23, 2026, the U.S. Food and Drug Administration approved Furoscix ReadyFlow ™ (furosemide injection) for the treatment of edema (fluid overload) in adults with heart failure or chronic kidney disease.Unregistered sale of equity · Form 8-K
- Jun 2, 2026On May 29, 2026, we announced that the U.S. Food and Drug Administration (FDA) approved Afrezza®(insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes.Other event · Form 8-K
- May 28, 2026Regulatory Update In connection with the approval of the Biologics License Application (“BLA”) for Afrezza in June 2014, the U.S. Food and Drug Administration (“FDA”) required us to conduct a five-year, randomized, controlled trial in 8,000-10,000 patients with type 2 diabetes to assess the risk of pulmonary …Other event · Form 8-K
- May 6, 2026MannKind Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Feb 26, 2026MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
- Nov 10, 2025On November 10, 2025, MannKind Corporation (the “Company”) announced that it is discontinuing its Phase 3 clinical trial evaluating nebulized inhalation suspension of clofazimine (“MNKD-101”) for the treatment of refractory nontuberculous mycobacterial (“NTM”) lung disease (the “ICoN-1 Study”)Other event · Form 8-K
- Nov 5, 2025Conference call today at 9:00 am ET.Earnings release · press release
- Oct 9, 2025Contingent Value Rights Agreement Pursuant to the Merger Agreement, on October 7, 2025, the Company and the Rights Agent entered into the Contingent Value Rights Agreement (the “CVR Agreement”) governing the terms of the CVRs issued pursuant to the Offer and the Merger (as defined below)Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…